FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Blood 2004 Nov 29;104(10):3038-45. Epub 2004 Jul 29.

Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

A novel oncogenic mutation (FIP1L1-PDGFRA), which results in a constitutively activated platelet-derived growth factor receptor-alpha (PDGFRA), has been invariably associated with a primary eosinophilic disorder. The current study examines both the prevalence and the associated clinicopathologic features of this mutation in a cohort of 89 adult patients presenting with an absolute eosinophil count (AEC) of higher than 1.5 x 10(9)/L. A fluorescence in situ hybridization (FISH)-based strategy was used to detect FIP1L1-PDGFRA in bone marrow cells. None of 8 patients with reactive eosinophilia displayed the abnormality, whereas the incidence of FIP1L1-PDGFRA in the remaining 81 patients with primary eosinophilia was 14% (11 patients). None (0%) of 57 patients with the hypereosinophilic syndrome (HES) but 10 (56%) of 19 patients with systemic mast cell disease associated with eosinophilia (SMCD-eos) carried the specific mutation. The bone marrow mast cell infiltration pattern in FIP1L1-PDGFRA(+) SMCD-eos was distinctly diffuse with loose tumoral aggregates. Treatment with low-dose imatinib (100 mg/d) produced complete and durable responses in all 8 FIP1L1-PDGFRA(+) cases treated. In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis.

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-03-07
Publisher Site
http://dx.doi.org/10.1182/blood-2004-03-0787DOI Listing
November 2004
13 Reads

Publication Analysis

Top Keywords

bone marrow
8
primary eosinophilia
8
mast cell
8
patients
7
eosinophilia
5
fip1l1-pdgfra
5
hypereosinophilic syndrome
4
patients hypereosinophilic
4
patients patients
4
carried specific
4
eosinophilia 14%
4
14% patients
4
syndrome 56%
4
56% patients
4
eosinophilia smcd-eos
4
cell disease
4
disease associated
4
systemic mast
4
smcd-eos carried
4
patients systemic
4

References

(Supplied by CrossRef)

Similar Publications